ISCO
vs
S&P 500
ISCO
S&P 500
Over the past 12 months, ISCO has significantly outperformed S&P 500, delivering a return of +55% compared to the S&P 500's +12% growth.
Stocks Performance
ISCO vs S&P 500
Performance Gap
ISCO vs S&P 500
Performance By Year
ISCO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
International Stem Cell Corp
Glance View
International Stem Cell Corp. operates as a clinical stage biotechnology company. The company is headquartered in Carlsbad, California. The company went IPO on 2006-09-25. The firm is focused on therapeutic and biomedical product development. The firm's segments include therapeutic market, anti-aging market and biomedical market. The firm is primarily a research and development company, for the therapeutic market, which is focused on clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The firm's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC) that develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
